Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy

NCT00300729

Last updated date
Study Location
Department of Pulmonary Medicine and Allergology, Sahlgrenska University Hospital
Gothenburg, , 413 45, Sweden
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Non-Small Cell Lung Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).

- Age at least 18 years. No upper age limit.

- Disease stage IIIB or IV.

- Performance status (WHO) 0-2

- Treatment with curative intent is not possible

- No prior chemotherapy for the present disease

- Planned treatment is palliative chemotherapy

- WBC count at least 3.0, platelet count at least 100

- Bilirubin < 1.5 * upper reference limit (URL), ASAT and ALAT < 3 * URL (<5 in case of liver metastases)

- Calculated creatinine clearance at least 40 mg/ml

- Informed oral and written consent

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Regular use of NSAID (except ASA at a dose of 50-100 mg daily)


- Active duodenal ulcer, ongoing gastrointestinal bleeding or inflammatory bowel disease


- Serious heart failure or serious liver disease


- Hypersensitivity so sulfonamides


- Pregnancy


- Lactation

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Non-Small Cell Lung CancerStudy of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)
NCT02920450
  1. Gainesville, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CancerEffect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
NCT00300729
  1. Gothenburg,
  2. Jönköping,
  3. Kalmar,
  4. Linköping,
  5. Lund,
  6. Malmö,
  7. Skövde,
  8. Trollhättan,
  9. Uddevalla,
  10. Umeå,
  11. Uppsala,
  12. Ystad,
  13. Örebro,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CancerA Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00555256
  1. St. Louis, Missouri
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-small Cell Lung CancerAn Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
NCT03915951
  1. Boston, Massachusetts
  2. Middletown, New Jersey
  3. Pompton Plains, New Jersey
  4. Commack, New York
  5. Harrison, New York
  6. New York, New York
  7. New York, New York
  8. Uniondale, New York
  9. Houston, Texas
  10. Via Albertoni, Bologna
  11. Via Albertoni, Bologna
  12. Via Massarenti, Bologna
  13. Via Massarenti, Bologna
  14. Via Massarenti, Bologna
  15. Via Palagi, Bologna
  16. Milan, Lombardia
  17. Milan, Lombardia
  18. Milan, Lombardia
  19. Milan, Lombardia
  20. Milan, Lombardia
  21. Milan, Lombardia
  22. Milan, Lombardia
  23. Viale Pansini, Napli
  24. Amsterdam, Noord-holland
  25. Amsterdam,
  26. Groningen,
  27. Groningen,
  28. Cordoba,
  29. Los Angeles, California
  30. Santa Monica, California
  31. Norwich, Connecticut
  32. Norwich, Connecticut
  33. Altamonte Springs, Florida
  34. Bonita Springs, Florida
  35. Bradenton, Florida
  36. Brandon, Florida
  37. Cape Coral, Florida
  38. Clearwater, Florida
  39. Fleming Island, Florida
  40. Fort Myers, Florida
  41. Fort Myers, Florida
  42. Gainesville, Florida
  43. Largo, Florida
  44. Lecanto, Florida
  45. Naples, Florida
  46. New Port Richey, Florida
  47. Ocala, Florida
  48. Orange City, Florida
  49. Orlando, Florida
  50. Port Charlotte, Florida
  51. Saint Petersburg, Florida
  52. Saint Petersburg, Florida
  53. Sarasota, Florida
  54. Sarasota, Florida
  55. Spring Hill, Florida
  56. Tallahassee, Florida
  57. Tallahassee, Florida
  58. Tampa, Florida
  59. Tavares, Florida
  60. The Villages, Florida
  61. Venice, Florida
  62. Winter Park, Florida
  63. Atlanta, Georgia
  64. Atlanta, Georgia
  65. Atlanta, Georgia
  66. Atlanta, Georgia
  67. Johns Creek, Georgia
  68. Chicago, Illinois
  69. Overland Park, Kansas
  70. Baltimore, Maryland
  71. Baltimore, Maryland
  72. Baltimore, Maryland
  73. Baltimore, Maryland
  74. Boston, Massachusetts
  75. Boston, Massachusetts
  76. Boston, Massachusetts
  77. Boston, Massachusetts
  78. Boston, Massachusetts
  79. Boston, Massachusetts
  80. Chelsea, Massachusetts
  81. Stoneham, Massachusetts
  82. Stoneham, Massachusetts
  83. Creve Coeur, Missouri
  84. Independence, Missouri
  85. Kansas City, Missouri
  86. Saint Louis, Missouri
  87. Saint Louis, Missouri
  88. Saint Louis, Missouri
  89. Saint Louis, Missouri
  90. Basking Ridge, New Jersey
  91. Hackensack, New Jersey
  92. Montvale, New Jersey
  93. Bronx, New York
  94. Bronx, New York
  95. Bronx, New York
  96. New York, New York
  97. New York, New York
  98. New York, New York
  99. Durham, North Carolina
  100. Columbus, Ohio
  101. Columbus, Ohio
  102. Columbus, Ohio
  103. Columbus, Ohio
  104. Columbus, Ohio
  105. Columbus, Ohio
  106. Columbus, Ohio
  107. Gahanna, Ohio
  108. Lewis Center, Ohio
  109. Clackamas, Oregon
  110. Newberg, Oregon
  111. Portland, Oregon
  112. Portland, Oregon
  113. Pittsburgh, Pennsylvania
  114. Pittsburgh, Pennsylvania
  115. Pittsburgh, Pennsylvania
  116. Pittsburgh, Pennsylvania
  117. York, Pennsylvania
  118. Chattanooga, Tennessee
  119. Chattanooga, Tennessee
  120. Chattanooga, Tennessee
  121. Cleveland, Tennessee
  122. Dickson, Tennessee
  123. Franklin, Tennessee
  124. Gallatin, Tennessee
  125. Hendersonville, Tennessee
  126. Hermitage, Tennessee
  127. Lebanon, Tennessee
  128. Murfreesboro, Tennessee
  129. Nashville, Tennessee
  130. Nashville, Tennessee
  131. Nashville, Tennessee
  132. Nashville, Tennessee
  133. Shelbyville, Tennessee
  134. Smyrna, Tennessee
  135. Houston, Texas
  136. Houston, Texas
  137. Kingwood, Texas
  138. Shenandoah, Texas
  139. The Woodlands, Texas
  140. Seattle, Washington
  141. Faenza, Emilia-romagna
  142. Lugo, Emilia-romagna
  143. Ravenna, Emilia-romagna
  144. Ravenna, Emilia-romagna
  145. Rimini, Emilia-romagna
  146. Roma, Lazio
  147. Milano, Lombardia
  148. Napoli, Naples
  149. Cattolica, Rimini
  150. Orbassano, Torino
  151. Orbassano, Torino
  152. Orbassano, Torino
  153. Orbassano, Torino
  154. Orbassano, Torino
  155. Orbassano, Torino
  156. Orbassano, Torino
  157. Milano,
  158. Napoli,
  159. Torino,
  160. Goyang-si, Gyeonggido
  161. Jeonnam,
  162. Seoul,
  163. Seoul,
  164. Seoul,
  165. Amsterdam, Noord-holland
  166. Majadahonda, Madrid
  167. Malaga, Málaga
  168. Barcelona,
  169. Barcelona,
  170. Barcelona,
  171. Barcelona,
  172. Barcelona,
  173. Cordoba,
  174. Cordoba,
  175. Esplugues de Llobregat,
  176. Hospitalet de Llobregat,
  177. L'Hospitalet,
  178. Madrid,
  179. Madrid,
  180. Malaga,
  181. Sevilla,
  182. Sevilla,
  183. Sevilla,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
Official Title  ICMJE Cox-2-Inhibitor and Chemotherapy in Non-Small Cell Lung Cancer. A Prospective Randomized Double-Blind Study
Brief Summary The primary purpose of the study is to investigate if daily treatment with celecoxib, an inhibitor of cyclooxygenase-2, can prolong survival in patients with advanced non-small cell lung cancer who receive anticancer chemotherapy as their primary treatment. Secondary endpoints of the study are: health-related quality of life, toxicity, cardiovascular events, progression-free survival, and biological markers (VEGF, proteomics).
Detailed Description

The study (CYCLUS trial, CY-cyclooxygenase-2 inhibitor, Chemotherapy, LUng cancer, Survival) is a prospective randomized double-blind multicenter trial. Patients are randomized to receive celecoxib at a dose of 400 mg b.i.d. or placebo. Primary endpoint of the trial is survival. Secondary endpoints are: quality of life, progression-free survival, toxicity, cardiovascular events, and biological parameters (plasma VEGF and proteomics).

The rationale behind the study consists of preclinical observations of antitumor effect of celecoxib in NSCLC. Inhibition of angiogenesis and proliferation as well as increased apoptosis has been demonstrated. In addition, pilot studies have shown that the combination of chemotherapy and celecoxib is feasible. No unexpected toxicity has been recorded in such trials. Furthermore, a randomized study of indomethacin, prednisolone or placebo in other types of advanced cancer, mainly gastrointestinal, showed a survival advantage for patients receiving antiinflammatory treatment.

Chemotherapy is given according to the current standard of the participating institution. In practice, patients will usually receive either carboplatin + gemcitabine or carboplatin + vinorelbine. Treatment duration with chemotherapy is 4 cycles (cycle length 3 weeks) in the absence of tumour progression or prohibitive toxicity.

Treatment with the study drug starts on the first day of cancer chemotherapy. Maximum treatment duration is one year. Treatment will be stopped earlier in case of objective tumor progression, serious toxicity that is considered to be related to the study drug or if the patient wants to stop treatment.

The size of the study is based on the hypothesis that celecoxib could prolong median survival by 8 weeks as compared to 7.5 months in the placebo group. With standard statistical requirements (type I error 5%, type II error 20%), the calculated number of patients was 760.

The study was supported by the Swedish Lung Cancer Study Group and organized as a multicenter trial, with participation of seven university hospitals and six smaller hospitals. The number of new cases of NSCLC stage IIIB-IV and performance status 0-2 in Sweden is around 1200/year. It was expected that 20% of the patients could be included in the study, which would make completion possible in three years.

The study was opened for randomization on May 31, 2006. Recruitment of patients was lower than expected. The study was closed for further randomization on May 31, 2009, as originally planned. 319 patients were included. Since maximum duration of treatment with the study drug is one year, the code will be broken after May 31, 2010. Data analysis is planned to take place in summer and autumn, 2010.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Non-Small Cell Lung Cancer
Intervention  ICMJE
  • Drug: Celecoxib
    Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
    Other Names:
    • Celebra
    • Onsenal
  • Drug: Placebo
    One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
Study Arms  ICMJE
  • Active Comparator: Celecoxib
    Four cycles of combination chemotherapy, usually with carboplatin + gemcitabine or carboplatin + vinorelbine, plus celecoxib 400 mg b.i.d. Treatment with celecoxib is continued after completion of chemotherapy. Maximum treatment duration is one year.
    Intervention: Drug: Celecoxib
  • Placebo Comparator: Placebo
    Chemotherapy as in arm 1 plus placebo capsules, b.i.d.
    Intervention: Drug: Placebo
Publications * Koch A, Bergman B, Holmberg E, Sederholm C, Ek L, Kosieradzki J, Lamberg K, Thaning L, Ydreborg SO, Sörenson S; Swedish Lung Cancer Study Group. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer. 2011 Jul;47(10):1546-55. doi: 10.1016/j.ejca.2011.03.035. Epub 2011 May 10.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Actual Enrollment  ICMJE
 (submitted: June 29, 2009)
319
Original Enrollment  ICMJE
 (submitted: March 8, 2006)
760
Estimated Study Completion Date  ICMJE September 2010
Estimated Primary Completion Date May 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
  • Age at least 18 years. No upper age limit.
  • Disease stage IIIB or IV.
  • Performance status (WHO) 0-2
  • Treatment with curative intent is not possible
  • No prior chemotherapy for the present disease
  • Planned treatment is palliative chemotherapy
  • WBC count at least 3.0, platelet count at least 100
  • Bilirubin < 1.5 * upper reference limit (URL), ASAT and ALAT < 3 * URL (<5 in case of liver metastases)
  • Calculated creatinine clearance at least 40 mg/ml
  • Informed oral and written consent

Exclusion criteria:

  • Regular use of NSAID (except ASA at a dose of 50-100 mg daily)
  • Active duodenal ulcer, ongoing gastrointestinal bleeding or inflammatory bowel disease
  • Serious heart failure or serious liver disease
  • Hypersensitivity so sulfonamides
  • Pregnancy
  • Lactation
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Sweden
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00300729
Other Study ID Numbers  ICMJE SLCSG0501
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Sverre Sörenson, MD, PhD, Swedish Lung Cancer Study Group
Study Sponsor  ICMJE University Hospital, Linkoeping
Collaborators  ICMJE
  • Swedish Lung Cancer Study Group
  • Pfizer
Investigators  ICMJE
Study Chair:Sverre Sörenson, MD, PhDDepartment of Medicine, Ryhov County Hospital, Jönköping, Sweden, Department of Pulmonary Medicine, University Hospital, Linköping, Sweden, and Department of Medical and Health Sciences, Linköping University, Sweden
Principal Investigator:Andrea Koch, MDAllergy Centre, University Hospital, Linköping, Sweden, Department of Pulmonary Medicine, University Hospital, Linköping, Sweden, and Department of Medical and Health Sciences, Linköping University, Sweden
PRS Account University Hospital, Linkoeping
Verification Date June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP